Side-by-side · Research reference
PT-141vsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED13/41 cited
BPhase 3HUMAN-REVIEWED25/54 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
PT-141
Survodutide
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
—
—
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
—
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Survodutide
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Not yet disclosed (Phase 3 ongoing)
SYNCHRONIZE Phase 3 program underway.Rubino 2026
Frequency
PRN, max 8 doses / month
Once weekly
Lower / starter dose
1 mg (off-label)
—
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Phase 2 RCT (obesity) · Phase 3 ongoing
Duration
PRN; reassess if no benefit after 8 doses
—
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
—
Timing
≥45 min before sexual activity
—
03Metabolic / Fat Loss Evidence
Parameter
PT-141
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
PT-141
Survodutide
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
—
Headache
Common
—
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
—
Cardiovascular disease
Use caution; transient BP rise
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
PT-141
Survodutide
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Injection site
SQ — abdomen or thigh.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.